Eckert & Ziegler: Radiopharmaceuticals segment to be restructured

Berlin, 20 September 2007 - As part of its acquisition of former MC Pharma GmbH (now Eckert & Ziegler EURO PET Köln-Bonn GmbH), Eckert & Ziegler AG (ISIN DE0005659700) increased its share of Eckert & Ziegler f-con Europe GmbH from 51% to 61% and decided to restructure its cyclotron product division. In the course of this change, Axel Schmidt will assume responsibility for all the Group's cyclotron products and Kathleen Siegert will be appointed a new managing director of the Eckert & Ziegler f-con Europe GmbH division holding. She succeeds the transitional managing director Ron Littmann. Executive Board chairman Dr. Andreas Hey, who was in charge of establishing the Radiopharmaceuticals segment over recent years, will not be renewing his contract and will leave the Group as of 31 December 2007. His responsibilities will be assumed by Dr. Andreas Eckert until further notice.

The production and sales of radioactive contrast agents for PET scans (Positron Emission Tomography), an imaging process for diagnosing various types of cancer, are distributed among different regional subsidiaries and share companies within the Group. Thus far they have not been under a single management. In the new structure, responsibilities will be centralized Europe-wide and processes reordered. The Group thereby expects to achieve greater customer proximity, reduced need for internal coordination, and higher profitability. It anticipates a net profit for the cyclotron product division and sales of ten million euros for the first time in 2008.

In addition to cyclotron products, the Radiopharmaceuticals segment of Eckert & Ziegler AG includes systems and automation technology for radiopharmaceutical production. Marketed under the "Modular Lab" brand name, these systems will not be affected by the restructuring measures.

The Board of Directors